New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018
According to new data from the National Health Expenditures (NHE), retail medicine pricesdeclined by 1% and retail medicine spendinggrew just 2.5% in 2018. To put that in context, hospital spending, which continued to account for one-third of all health care spending, grew by 4.5%, and physicians and clinical services grew by 4.1%. This data, published inHealth Affairs, underscores how policies that single out prescription medicine won ’t fix soaring health care costs or lower out-of-pocket costs for Americans.  (Source: The Catalyst)
Source: The Catalyst - December 6, 2019 Category: Pharmaceuticals Tags: Out of Pocket Costs hospitals Let's Talk About Cost Source Type: news

New poll:  76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines
The House of Representatives has spent much of this fall focused on Speaker Pelosi ’s drug pricing bill,H.R.3, buta recent survey of nearly 2,000 registered voters confirms that H.R.3 is not the right solution. In fact, voters have significant concerns and a large majority outright opposes it. (Source: The Catalyst)
Source: The Catalyst - December 5, 2019 Category: Pharmaceuticals Tags: Research and Development Economic Impact Pelosi Plan Source Type: news

Guest post: H.R.3 is the wrong approach to help patients like me
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today. (Source: The Catalyst)
Source: The Catalyst - November 26, 2019 Category: Pharmaceuticals Authors: Guest Contributor Tags: diabetes chronic disease Voters for Cures Pelosi Plan Source Type: news

Speaker Pelosi ’s drug pricing plan could result in 56 fewer new medicines over 10 years
Anew analysis from economic consulting firm Vital Transformation shows that Speaker Nancy Pelosi ’s drug pricing plan,H.R.3, could result in at least 56 fewer innovative medicines for patients over 10 years. The study examined the impact of foreign reference pricing provisions in H.R.3 on treatments and cures from small, emerging biotech companies that rely on venture capital to finance their research and development (R&D). (Source: The Catalyst)
Source: The Catalyst - November 21, 2019 Category: Pharmaceuticals Authors: Juliet Johnson Tags: Research and Development ALS Rare Diseases Alzheimer's Pelosi Plan Source Type: news

Pelosi ’s radical plan would leave patients with sickle cell disease behind
Sickle cell disease (SCD) is the most commonly inherited genetic blood disorder, affecting nearly 100,000 children and adults in the United States. Three million Americans carry the sickle cell trait and it is nearly25 times more common in people of African American descent. The disorder, which can cause irregularly shaped blood cells to get stuck in narrow vessels, inflicts substantial pain on patients. The resulting reduced oxygen flow creates life-threatening complications such as difficulty breathing, chest pains, blood clots and stroke. (Source: The Catalyst)
Source: The Catalyst - November 14, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Rare Diseases Pelosi Plan Source Type: news

R & D Focus: It takes an ecosystem to deliver innovative new therapies
We are living in a new era of medicine where innovations are transforming our ability to attack the cause of a disease, not just the symptoms. Today, concepts, such ascell and gene therapies,that once sounded like science fiction are now becoming reality with the potential to cure or fundamentally alter the trajectory of many life-threatening conditions. This rapid state of innovation is due in part to the vast array of partnerships between government, the biopharmaceutical industry and academia that make up the biomedical research and development (R&D) ecosystem, which enables us to expand the frontier of science. (Source: The Catalyst)
Source: The Catalyst - November 14, 2019 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Research and Development Pelosi Plan & D Focus Source Type: news

PhRMA submission to 2020 National Trade Estimate Report: Urgent action required to protect U.S. biopharmaceutical innovation
International trade policy plays a critical role in ensuring that the U.S. biopharmaceutical industry can continue to develop and provide both American and international patients with access to innovative, life-saving medicines. Unfortunately, in many countries across the world, a host of trade barriers, discriminatory measures and the failure to comply with international commitments impedes – or even prevents – this access. (Source: The Catalyst)
Source: The Catalyst - November 8, 2019 Category: Pharmaceuticals Authors: Douglas Petersen Tags: Research and Development trade Research and Investment Source Type: news

Pelosi ’s radical plan would leave patients with rare pediatric diseases behind
There are about 7,000 rare diseases and half of these affect children. According to the National Institutes of Health (NIH), 30 million Americans, or 10 percent of the population, have one of the nearly 7,000 known rare diseases. A disease is defined as a rare or orphan disease when it affects fewer than 200,000 people in the United States. (Source: The Catalyst)
Source: The Catalyst - November 7, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Rare Diseases Pelosi Plan Source Type: news

Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter
(Source: The Catalyst)
Source: The Catalyst - November 7, 2019 Category: Pharmaceuticals Authors: Guest Contributor Tags: Value-Driven Health Care The Value Collaborative Source Type: news

IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical innovation. While these strong IP protections promote innovation and pave the way for the research and development (R&D) of new medicines for patients, they also have a tremendous impact on the U.S. economy. In fact, last yearPhRMA member companies invested a record-setting $79.6 billion in R&D– driving unprecedented advancements to find new treatments and cures for patients. (Source: The Catalyst)
Source: The Catalyst - November 4, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Economic Impact Intellectual Property Research and Investment IP Explained Source Type: news

New data show how ICER ’s value framework could prevent or delay access to treatments for Medicaid patients across the country
Anew analysis from Xcenda applied the Institute for Clinical and Economic Review ’s (ICER) value assessments to state Medicaid programs inCalifornia,Massachusetts,Maryland,NevadaandNew York. The study found these one-size-fits-all value assessments could prevent or delay access to prescriptions to treat serious, complex conditions like multiple sclerosis (MS), rheumatoid arthritis (RA), non-small cell lung cancer (NSCLC) and psoriasis. (Source: The Catalyst)
Source: The Catalyst - November 4, 2019 Category: Pharmaceuticals Authors: Katie Koziara Tags: Access Medicaid Value-Driven Health Care The Value Collaborative Source Type: news

What they are saying: Negative impact of Pelosi ’s plan on biopharmaceutical innovation
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that would be thewrong approach for patients, the U.S. health care system and theeconomy. (Source: The Catalyst)
Source: The Catalyst - October 31, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Economic Impact Research and Investment Pelosi Plan Source Type: news

Pelosi ’s radical plan leaves lung cancer patients behind
Lung cancer is the second most common form of cancer in men and women and the leading cause of cancer-related deaths in the United States. In 2019 alone, there will be an estimated 228,000 new lung cancer diagnoses and 140,000 deaths from the disease. Although diagnostic capabilities to detect lung cancer have crossed anew frontier, with identification down to the genetic level, continued biopharmaceutical research is needed to increase survival rates and ensure patients are diagnosed as early as possible. (Source: The Catalyst)
Source: The Catalyst - October 23, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Economic Impact Research and Investment Pelosi Plan Source Type: news

Guest post: Sharing discounts and rebates is the right thing to do
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today. (Source: The Catalyst)
Source: The Catalyst - October 21, 2019 Category: Pharmaceuticals Authors: Guest Contributor Tags: diabetes Out of Pocket Costs Voters for Cures Source Type: news

PhRMA CEO in STAT: Pelosi ’s drug pricing plan puts medical innovation at risk
The following op-ed was authored by PhRMA president and CEO Stephen J. Ubl and published in STAT First Opinionhere on October 17, 2017.The future of medical innovation in America is at a crossroads.Biopharmaceutical science is accelerating at a record pace, leading to new discoveries that are radically reshaping our ability to fight disease. At the same time, politicians in Washington, D.C., are considering legislation to lower drug costs this week that threatens this progress and would put us on a path to government-run health care.As president and CEO of PhRMA, I recently got a chance to meet with scientists and tour the...
Source: The Catalyst - October 17, 2019 Category: Pharmaceuticals Source Type: news

Pelosi ’s radical plan would leave Alzheimer’s patients behind
Last month, House Speaker Nancy Pelosi unveiled aradical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and leave U.S. patients behind. Take for example, Alzheimer ’s disease, a ruthless disease which devastates the minds of 5.7 million Americans and creates substantial burdens for families and caregivers. (Source: The Catalyst)
Source: The Catalyst - October 16, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Economic Impact Medicare Research and Investment Source Type: news

Event tomorrow: Maintaining America ’s leadership in access and innovation
Each year,biopharmaceutical companies invest nearly $100 billion in the discovery of new treatments and cures. Despite a challenging research and development (R&D) process, consistently high levels of investment in biopharmaceutical innovation help support more than 4million jobs across the economy and secure America ’s position as the global leader in the development of new medicines, with over half of all new medicines coming from the U.S. At the same time, long-standing market-based policies have enabled the U.S. health care system to provide patients with access to more innovative medicines far earlier tha n ...
Source: The Catalyst - October 16, 2019 Category: Pharmaceuticals Tags: Research and Development Economic Impact Medicare Research and Investment Source Type: news

Pelosi ’s radical plan would leave ALS patients behind
Last month, House Speaker Nancy Pelosi unveiled aradical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and leave U.S. patients behind. For example,researchers are focused every day on finding new treatments and cures for amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig ’s Disease), but Pelosi’s plan could threaten future treatments for ALS by imposing government-set prices on critical medicines, creating increased uncertainty and eroding incentives for investment into risky research and development (R&D). (Source: The Catalyst)
Source: The Catalyst - October 15, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development ALS Source Type: news

Remembering Harrison Cook, Vice President for International Government Affairs at Eli Lilly and Company
Guest authors of this blog are: (Source: The Catalyst)
Source: The Catalyst - October 11, 2019 Category: Pharmaceuticals Authors: Guest Contributor Tags: International Source Type: news

What They Are Saying: Broad Opposition to Pelosi ’s Radical Drug Pricing Plan
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan that would be thewrong approach for patients, the U.S. health care system,economy, and American innovation. An increasing number of stakeholders, experts and policymakers have also spoken out in broad opposition to the Pelosi plan. Here are some of their thoughts: (Source: The Catalyst)
Source: The Catalyst - October 10, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Economic Impact Medicare Research and Investment Source Type: news

Nearly 140 medicines in development to treat mental illness
Today is World Mental Health Day, a moment where we reflect about the challenges we still face towards better treatment of mental illness and its impact on patients. (Source: The Catalyst)
Source: The Catalyst - October 10, 2019 Category: Pharmaceuticals Tags: Medicines in Development Mental Health New Era of Medicine Source Type: news

IP Explained: FACT CHECK: March-In Authority and the Bayh-Dole Act
In our lastIP Explained post, we outlined how the Bayh-Dole Act laid the foundation for effective technology transfer across industries in the United States and helps foster continued medical innovation that helps patients. (Source: The Catalyst)
Source: The Catalyst - October 9, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Intellectual Property IP Explained Source Type: news

More evidence that medicine prices are growing at slowest rate in decades
This week the White House Council of Economic Advisers (CEA) released yet another report showing that medicine prices are growing at the slowest rate in decades. The report, “Measuring Prescription Drug Prices: A Primer on the CPI Prescription Drug Index,” focuses on the Bureau of Labor Statistics’ (BLS) Consumer Price Index for prescription drugs (CPI-Rx).  According to the CEA, “list prices are perhaps the least important measure of price for prescription drugs” versus the CPI-Rx, which reflects actual prices received by pharmacies and accounts for changes in medicine utilization as new...
Source: The Catalyst - October 4, 2019 Category: Pharmaceuticals Tags: Drug Cost Let's Talk About Cost Source Type: news

On Manufacturing Day, a closer look at the biopharmaceutical sector ’s contributions
Each year, the first Friday in October marksManufacturing Day, an annual recognition of the critical role manufacturing-intensive industries play in powering innovation and generating jobs and economic growth for Americans. Some may not think about manufacturing when they think about their medicines, but America ’s biopharmaceutical sector has a significantadvanced manufacturing footprint. (Source: The Catalyst)
Source: The Catalyst - October 4, 2019 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Economic Impact Manufacturing Source Type: news

The truth about the marketing and promotion of medicines
Despite what critics say, the U.S. biopharmaceutical industry spends three times more on the research and development (R&D) of new treatments and cures than on the marketing and promotion of medicines. Misleading claims on how much is spent on marketing and promotion perpetuate a narrative riddled with inaccurate data and information and results in policy proposals that can harm patients. (Source: The Catalyst)
Source: The Catalyst - October 3, 2019 Category: Pharmaceuticals Tags: Research and Development Let's Talk About Cost Source Type: news

Survey shows out-of-pocket costs top health care concern for voters
Arecent national survey of 800 registered voters conducted by Public Opinion Strategies shows that health insurance premiums, deductibles and copays are the top health care concerns for Americans. In addition, a majority of respondents say they would prefer to pay a higher monthly premium in exchange for lower out-of-pocket costs. Americans support efforts that improve predictability in their out-of-pocket costs, ensure that insurers and pharmacy benefit managers (PBMs) pass along negotiated discounts directly to patients at the pharmacy counter, and get generic medicines to market faster. There is substantially less voter...
Source: The Catalyst - October 2, 2019 Category: Pharmaceuticals Tags: Drug Cost Out of Pocket Costs Let's Talk About Cost Source Type: news

By the Numbers: Pelosi ’s radical plan puts America’s economy and jobs at risk
We already know that the radical drug pricing plan unveiled last week by House Speaker Nancy Pelosi is thewrong approach for patients, the U.S. health care system, and American innovation. But what about our economy and jobs? (Source: The Catalyst)
Source: The Catalyst - September 26, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Economic Impact Research and Investment Source Type: news

ICYMI: Fighting for a cure to ALS
Yesterday at The Atlantic Festival, I had the chance to speak with Amy, a biopharmaceutical researcher focused on amyotrophic lateral sclerosis (ALS). As a young girl, Amy ’s father inspired her to become a scientist. Years later, his ALS diagnosis made her life’s work personal. (Source: The Catalyst)
Source: The Catalyst - September 25, 2019 Category: Pharmaceuticals Authors: Anne McDonald Pritchett, PhD Tags: Research and Development ALS Rare Diseases GoBoldly Source Type: news

4 Reasons Why the Radical Pelosi Plan is the Wrong Approach
Speaker of the House Nancy Pelosi recently unveiled a radical plan that would restrict and fundamentally change how patients access medicines in the United States. It would threaten our country ’s global leadership in developing innovative, lifesaving treatments and cures and force patients to face the uncertainty of a health care system where the government sets prices for critical medicines and import foreign determinations of the value of medicines. Such a system allows the government to dictate which disease areas are worthy of future research and represents a de facto nationalization of the innovative biopharmac...
Source: The Catalyst - September 25, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Drug Cost Out of Pocket Costs Prescription for Medicare Source Type: news

Four reasons why the radical Pelosi Plan is the wrong approach
Speaker of the House Nancy Pelosi recently unveiled a radical plan that would restrict and fundamentally change how patients access medicines in the United States. It would threaten our country ’s global leadership in developing innovative, lifesaving treatments and cures and force patients to face the uncertainty of a health care system where the government sets prices for critical medicines and import foreign determinations of the value of medicines. Such a system allows the government to dictate which disease areas are worthy of future research and represents a de facto nationalization of the innovative biopharmac...
Source: The Catalyst - September 24, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Drug Cost Out of Pocket Costs Prescription for Medicare Source Type: news

IP Explained: Will America Cede Global Medical Innovation Leadership to Asia?
Last month, Taiwan became the latest economy in Asia to take a bold step to bolster life sciences innovation and to accelerate economic growth. On August 20, 2019, Taiwan ’s Food and Drug Administrationbegan implementing a patent linkage system following adoption of an amendment to the Pharmaceutical Affairs Act earlier in the summer.  (Source: The Catalyst)
Source: The Catalyst - September 18, 2019 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Research and Development Intellectual Property biologics IP Explained Source Type: news

IP Explained: Four things to know about the Bayh-Dole Act
Thanks in large part to strong intellectual property protections – including policies that incentivize public and private investments in research and development (R&D) – the United States is theglobal leader in biopharmaceutical innovation. We ’vepreviously examined how the public and private sectors play complimentary roles with the biopharmaceutical industry doing the majority of R&D that translates basic science into new medicines. In today ’s IP Explained, we are going to take a closer look atthe Bayh-Dole Act and how it laid the foundation for effective technology transfer that moderniz...
Source: The Catalyst - September 13, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Intellectual Property IP Explained Source Type: news

Hospitals make 9 times more than physicians ’ offices on provider-administered medicines
Anew study, conducted by the Partnership for Health Analytic Research (PHAR), found that hospitals retained 91% of the total profit on physician-administered medicines in the commercial market that went to providers in 2016. The data also show that physicians retained just 9%, even though they treated a nearly equal number of patients. This further demonstrates just how muchhospitals are driving health care spending in the United States. (Source: The Catalyst)
Source: The Catalyst - September 10, 2019 Category: Pharmaceuticals Authors: Katie Koziara Tags: Drug Cost Out of Pocket Costs hospitals Let's Talk About Cost Source Type: news

Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today. (Source: The Catalyst)
Source: The Catalyst - September 4, 2019 Category: Pharmaceuticals Authors: Guest Contributor Tags: IPI Source Type: news

IP Explained: Three forms of IP protections for medicines
Intellectual property (IP) protections for the biopharmaceutical sector provide incentives that help to promote the discovery and development of life-saving medicines for patients and foster a competitive market for generic and biosimilar medicines. There are three forms of IP protections critical to biopharmaceutical development, and although they work together in a complementary fashion, each is distinct and governed by different statutory provisions. (Source: The Catalyst)
Source: The Catalyst - August 27, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: IP Explained Source Type: news

Three reasons the Senate Finance package is the wrong approach for patients
For more than a decade, Medicare Part D has successfully provided seniors and people with disabilities comprehensive prescription drug coverage, while its unique market-based structure has kept overall program costs far below initial projections. In fact, according to a newnationwide survey, nearly nine of ten seniors are satisfied with their Part D prescription drug coverage. Even so, increasingly beneficiaries are facing high out-of-pocket costs at the pharmacy counter. (Source: The Catalyst)
Source: The Catalyst - August 26, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Part D Prescription for Medicare Source Type: news

Fact Check: How hospitals continue to drive health care spending
There is a lot of talk about health care costs in the United States that is mostly centered on prescription medicine spending, overlooking the largest share of U.S. health care spending – hospital care. And hospital spending continues to grow as their prices increase. (Source: The Catalyst)
Source: The Catalyst - August 21, 2019 Category: Pharmaceuticals Tags: hospitals Let's Talk About Cost Source Type: news

340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients
Congress created the340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients. Unfortunately, many for-profit pharmacies and other third parties are taking advantage of the program by capturing some of these significant 340B discounts. (Source: The Catalyst)
Source: The Catalyst - August 20, 2019 Category: Pharmaceuticals Tags: 340B Pharmacy Benefit Managers hospitals 340B Spotlight Pharmacies Source Type: news

New analysis: Government intervention in Part B threatens patient access to medicines
Anew analysis from Avalere looked at how access to medicines in Part B may be impacted if the government only covered a certain list of medicines, an approach known as applying a national formulary. Unlike Medicare, the U.S. Department of Veterans Affairs (VA) uses a national formulary, and Avalere compared coverage for physician-administered medicines available to veterans through the VA with the 50 medicines with the most spending in Medicare Part B, excluding vaccines. The analysis revealed thatonly 26 of the Part B medicines – only half of them – are available to veterans through the VA’s national for...
Source: The Catalyst - August 19, 2019 Category: Pharmaceuticals Tags: Medicare Part B Prescription for Medicare Source Type: news

Three things to know about the Part D GAO report
The Government Accountability Office (GAO) recentlyreleased a new report looking at Medicare Part D and the role of Pharmacy Benefit Managers (PBMs) in the program. While the report provides a wealth of information about the growth of manufacturer rebates and discounts in Part D and provides helpful context in today ’s discussion about ways to improve the program, here are three facts about the report’s findings to keep in mind. (Source: The Catalyst)
Source: The Catalyst - August 16, 2019 Category: Pharmaceuticals Tags: Drug Cost Part D Out of Pocket Costs Let's Talk About Cost Source Type: news

Four Things You Should Know About AARP
As lawmakers in Washington consider policies to make changes to Medicare prescription drug coverage, one solution that would provide immediate relief is sharing the savings biopharmaceutical companies negotiate with insurers and pharmacy benefit managers (PBMs) with seniors at the pharmacy counter. Despite support from policymakers on both sides of the aisle and more than86% of AARP members, AARP continues to oppose policies that would enable sharing the savings with seniors, while receiving hundreds of millions of dollars in revenue from insurance companies every year.  (Source: The Catalyst)
Source: The Catalyst - August 14, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Source Type: news

What they ’re saying: Safety is top concern for recent drug importation proposal
Last week, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) released their “Safe Importation Action Plan,” which would allow importation of certain prescription drugs from Canada and other countries. Importing drugs, whether from Canada or elsewhere in the world, poses a huge safety risk and a broad range of stakeholders have expressed their concern about the plan. Dru g importation schemes increase the potential for counterfeit or adulterated products to infiltrate the U.S. pharmaceutical supply chain, putting Americans in harm’s way.  AsPhRMA Pr...
Source: The Catalyst - August 8, 2019 Category: Pharmaceuticals Tags: Safety Counterfeit Drugs Imported Drugs Importation Drug Importation Source Type: news

IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle
Patents are unique in that they are a form of IP protectionestablished in the U.S. Constitution that grants inventors the right to their inventions without others being able to make, use or sell them for a set period of time. Many essential industries rely on the U.S. patent system to foster innovation, and the existence of a patent doesn ’t necessarily prevent others from developing and patenting different solutions to the same problem. And once the patent has expired, the invention can be freely used by anyone. (Source: The Catalyst)
Source: The Catalyst - August 6, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Patents IP Explained Source Type: news

ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals
This week, the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration announced their “Safe Importation Action Plan.” While patients are rightfully concerned about the affordability of their medicine, the fact remains that there is no way to guarantee the safety of drugs that come into the country from outside the U.S. supply chain. (Source: The Catalyst)
Source: The Catalyst - August 1, 2019 Category: Pharmaceuticals Authors: Tiffany Haverly Tags: Prescription Drug Safety Drug Importation Source Type: news

IP Explained: Understanding biopharmaceutical innovation
Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer and hepatitis C, resulting in decreased death rates, longer life expectancy and better quality of life for patients. (Source: The Catalyst)
Source: The Catalyst - July 30, 2019 Category: Pharmaceuticals Tags: Research and Development Patents Intellectual Property IP Explained Source Type: news

IP Explained: Why IP protections are important for biologic medicines
Biologics are cutting-edge therapies that treat or cure some of the most challenging and costly diseases. These medicines are created from living organisms through highly complex manufacturing processes and include gene and cell therapies, therapeutic proteins, monoclonal antibodies and vaccines. In 2010, theBiologics Price Competition and Innovation Act (BPCIA) created an abbreviated regulatory approval pathway for biosimilars – a product that is “similar” to a biologic medicine that was already licensed by the U.S. Food and Drug Administration (FDA). Until Congress passed the BPCIA, there was no pathway...
Source: The Catalyst - July 18, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Intellectual Property Biologics and Biosimilars IP Explained Source Type: news

PhRMA member companies invested nearly $80 billion in R & D last year
Last year, PhRMA member companies invested a record-setting $79.6 billion in research and development (R&D) according to the2019 PhRMA member annual survey. (Source: The Catalyst)
Source: The Catalyst - July 18, 2019 Category: Pharmaceuticals Authors: Tim McClung Tags: Research and Development Drug Development Source Type: news

Setting the record straight on international reference pricing
There ’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability solutions for patients. Unfortunately, some proposals have centered on the misguided idea of having the governme nt set prices through a mechanism known as international reference pricing. Today, we’re taking a step back to examine what international reference pricing is and what it has meant for patients abroad. (Source: The Catalyst)
Source: The Catalyst - July 16, 2019 Category: Pharmaceuticals Authors: Kevin Haninger Tags: Access Drug Cost trade Part B Source Type: news

Four states adopt first-in-the-nation laws to protect patients from surprise insurer practices
West Virginia, Virginia, Arizona and Illinois recently became the first states in America to adopt patient-centered legislation to bring relief and more predictability to patients facing high out-of-pocket costs for prescription medicines. (Source: The Catalyst)
Source: The Catalyst - July 15, 2019 Category: Pharmaceuticals Authors: Nick McGee Tags: Out of Pocket Costs Let's Talk About Cost Source Type: news

New Let ’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?
For the last two years, ourLet ’s Talk About Cost campaign has sought to answer questions people have about their medicine costs and advance a dialogue on how we can make medicines more affordable for patients. Too often patients across America struggle to afford their medicines and we support solutions like ensuring discounts and rebates are shared with patients at the pharmacy counter. (Source: The Catalyst)
Source: The Catalyst - July 9, 2019 Category: Pharmaceuticals Authors: Priscilla VanderVeer Tags: Drug Cost Let's Talk About Cost Source Type: news